This week in therapeutics




Licensing status

Publication and contact information

Musculoskeletal disease

Bone repair; osteoporosis

Free fatty acid receptor 1 (FFAR1; GPR40)

Studies in mice suggest GPR40 agonists could help prevent bone loss. In mice, Gpr40 knockout decreased bone mineral density and bone volume compared with no knockout, and a GPR40 agonist prevented ovariectomy-associated bone loss. Next steps could include evaluating clinical-stage GPR40 agonists in mouse models of osteoporosis and bone loss.
Takeda Pharmaceutical Co. Ltd.'s TAK-875, a GPR40 agonist, is in Phase III testing to treat diabetes.
Connexios Life Sciences Pvt. Ltd. has two GPR40 agonists, CNX-011-326 and CNX-011-67, in preclinical development for the same indication.

SciBX 6(7); doi:10.1038/scibx.2013.165
Published online Feb. 21, 2013

Patent and licensing status unavailable

Wauquier, F. et al. J. Biol. Chem.; published online Jan. 18, 2013;
Contact: Yohann Wittrant, French National Institute for Agricultural Research (INRA), Clermont-Ferrand, France